Hado Therapeutics, a pioneering UK-based drug development company advancing next-generation therapeutics for unmet clinical needs, today announced a breakthrough discovery in collaboration with Professor Tim Palmer, Professor of Cardiovascular Biology, and Dr Katie Wraith, Lecturer in Cardiovascular Biology, both at the Hull York Medical School, University of Hull.
Together, the team has developed a novel therapeutic approach with the potential to address a broad spectrum of conditions involving impaired clotting, excessive bleeding, and inadequate tissue repair. This includes both rare genetic disorders and common post-surgical complications, with a particular focus on 1) post-operative bleeding, 2) bleeding disorders currently managed with antifibrinolytic drugs, and 3) inherited platelet function disorders.
“We believe this scientific advancement has the potential to redefine how we treat patients prone to excessive bleeding and poor tissue recovery,” said Dr Harsha Kantamneni, Chief Scientific Officer at Hado Therapeutics. “By collaborating with Professor Palmer and Dr Wraith—renowned for their cardiovascular biology expertise—we are translating cutting-edge research into targeted therapies with real-world clinical impact.”
The lead compound from this collaboration is currently undergoing preclinical validation, showing promising activity in restoring platelet function and enhancing tissue stability in early in vivo models. If successful, it could supplement or replace existing antifibrinolytic therapies with a safer, more precise mechanism of action.
Hado Therapeutics is actively seeking strategic investment partners to accelerate the development programme into clinical trials. The company plans to apply for Orphan Drug Designation for rare bleeding disorders and explore broader applications across cardiac surgery, autoimmune conditions, and neurovascular complications.
About Hado Therapeutics
Hado Therapeutics Ltd (UK Reg. 12240559), formerly known as Haiku Therapeutics, based at the Institute of Cancer Therapeutics, University of Bradford. Hado is a UK-based research company specialising in the development of precision medicines for high-risk and under-treated conditions. With core expertise in oncology, haematology, and neurodegeneration, the company is advancing a pipeline of innovative therapeutics that target the underlying biological mechanisms of complex diseases, driven by strong academic and clinical partnerships.About Professor Tim Palmer
Professor Tim Palmer leads cardiovascular biology research at Hull York Medical School (HYMS). His work focuses on endothelial function, thrombosis, and vascular repair. He brings decades of academic leadership and translational insight to the Hado Therapeutics development programme.About Dr Katie Wraith
Dr Katie Wraith is a Lecturer in Cardiovascular Biology at the University of Hull and an expert in the regulation of vascular inflammation, endothelial activation, and platelet interactions. Her research focuses on mechanisms of vascular dysfunction and blood cell signalling in disease and injury. She plays a pivotal role in bridging molecular biology with therapeutic innovation at Hado Therapeutics.Investor and Media Contact:
Harsha KantamneniFounder & CSO, Hado Therapeutics
📩 team@hadotherapeutics.co.uk
🌐 www.hadotherapeutics.co.uk
This announcement contains forward-looking statements relating to preclinical data and therapeutic potential. Actual results may differ based on regulatory review and future clinical outcomes.